Is adjuvant trastuzumab a cost-effective therapy for HER-2/neu-positive T1bN0 breast cancer?

C Skedgel, D Rayson, T Younis

Research output: Contribution to journalArticlepeer-review

14 Citations (Scopus)


In light of clinical uncertainty and the high acquisition costs of trastuzumab, we examined the value for money associated with concurrent or sequential trastuzumab in women with HER-2/neu-positive breast cancer with small node-negative tumours (T1bN0).
Original languageEnglish
Pages (from-to)1834-40
Number of pages7
JournalAnnals of Oncology
Issue number7
Publication statusPublished - Jul 2013


  • Adult
  • Aged
  • Aged 80 and over
  • Antibodies, Monoclonal Humanized)
  • Antineoplastic Agents
  • Breast Neoplasms
  • Chemotherapy (Adjuvant)
  • Cost-Benefit Analysis
  • Female
  • Humans
  • Middle Aged
  • Models (Economic)
  • Neoplasm Recurrence (Local)
  • Neoplasm Staging
  • Quality-Adjusted Life Years
  • Receptor (ErbB-2)
  • Risk
  • Treatment Outcome

Cite this